Sabrina Sharmin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sabrina Sharmin has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Asef Raj
School of Pharmacy BRAC University Dhaka Bangladesh
2 shared publicationsA B M Alauddin Chowdhury
Daffodil International University , Dhaka, Dhaka , Bangladesh
1 shared publicationAbu Hena Md. Saiful Karim Chowdhury
Shaheed Suhrawardy Medical College, Dhaka, Bangladesh
1 shared publicationAdwiza Chakraborty Bishakha
School of Pharmacy, BRAC University, Dhaka, Bangladesh
1 shared publicationAnika Awal Omi
BIRDEM General Hospital Dhaka Bangladesh
1 shared publication- Aslam Hossain
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh, du.ac.bd
1 shared publication
Latest Publications
- Open Access
- 6 October 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (10)
A Narrative Review on the Recent Insights Into the Pathogenicity and Potential Role of Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) in the Emergence of “Disease X”
Background and Aims: Following the end of the COVID‐19 global emergency, concern has shifted to “Disease X,” a hypothetical, highly transmissible, and deadly pathogen, and Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) is a prime candidate for this. This review explores its epidemiology, mutations, transmission, and potential to become a pandemic‐capable pathogen, aiming to support future research and public health preparedness against the disease. Methods: A comprehensive search of major databases was conducted for peer‐reviewed English articles (2000–2025) focusing on virology, outbreaks, treatments, and public health using relevant but definite keywords. Studies met strict inclusion criteria and standardized methods to ensure quality, reproducibility, and transparency. Results: Since it was identified in 2012, MERS‐CoV has spread across 27 countries, presenting a high case fatality rate (~34.5%) and zoonotic origin. It is primarily linked to dromedary camels, but shows limited human‐to‐human transmission ( R ₀ < 1). Unlike SARS‐CoV‐2, MERS‐CoV's spread is confined to close contact and healthcare settings, largely in the Middle East and parts of Africa. Its pathogenesis involves severe respiratory illness, driven by immune evasion and systemic inflammation, especially in individuals with comorbidities. While MERS‐CoV lacks pandemic‐level transmissibility, its genetic plasticity poses a risk for future evolution. Vaccine and therapeutic development remain limited due to sporadic outbreaks and low global urgency. Conclusion: Despite not currently fitting the Disease X archetype, MERS‐CoV's high mortality, zoonotic spillover potential, and possibility for increased transmissibility warrant continued surveillance, targeted research, and strengthened public health infrastructure to prevent localized outbreaks from escalating into broader crises.
- 6 October 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (10)
Open AccessA Narrative Review on the Recent Insights Into the Pathogenicity and Potential Role of Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) in the Emergence of “Disease X”
Background and Aims: Following the end of the COVID‐19 global emergency, concern has shifted to “Disease X,” a hypothetical, highly transmissible, and deadly pathogen, and Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) is a prime candidate for this. This review explores its epidemiology, mutations, transmission, and potential to become a pandemic‐capable pathogen, aiming to support future research and public health preparedness against the disease. Methods: A comprehensive search of major databases was conducted for peer‐reviewed English articles (2000–2025) focusing on virology, outbreaks, treatments, and public health using relevant but definite keywords. Studies met strict inclusion criteria and standardized methods to ensure quality, reproducibility, and transparency. Results: Since it was identified in 2012, MERS‐CoV has spread across 27 countries, presenting a high case fatality rate (~34.5%) and zoonotic origin. It is primarily linked to dromedary camels, but shows limited human‐to‐human transmission ( R ₀ < 1). Unlike SARS‐CoV‐2, MERS‐CoV's spread is confined to close contact and healthcare settings, largely in the Middle East and parts of Africa. Its pathogenesis involves severe respiratory illness, driven by immune evasion and systemic inflammation, especially in individuals with comorbidities. While MERS‐CoV lacks pandemic‐level transmissibility, its genetic plasticity poses a risk for future evolution. Vaccine and therapeutic development remain limited due to sporadic outbreaks and low global urgency. Conclusion: Despite not currently fitting the Disease X archetype, MERS‐CoV's high mortality, zoonotic spillover potential, and possibility for increased transmissibility warrant continued surveillance, targeted research, and strengthened public health infrastructure to prevent localized outbreaks from escalating into broader crises.
- Open Access
- 16 July 2025
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 9, 100228
Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation
- 16 July 2025
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 9, 100228
Open AccessHarnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation
- Open Access
- 1 January 2025
- Published by Wiley in BioMed Research International
- Vol. 2025 (1)
Phenolic Compounds of Justicia gendarussa Show Pharmacological Potentials Against Pain, Oxidation, Hyperglycemia, Diarrhea, and Microbes: Phytopharmacological and Computational Approaches
Background: Justicia gendarussa is a branched shrub spread across Indian, Sri Lankan, and Malaysian forests. It has been widely used across many countries to treat asthma, rheumatism, colics in children, eczema, and HIV. The study goal was to investigate the phytoconstituents from J. gendarussa and to discover its therapeutic potential against various disease conditions. Methods: The plant sample was collected, dried, and grinded into coarse powder which was then soaked in methanol for 2 weeks. After the maceration process, the crude methanolic extract was subjected to solvent–solvent partitioning into four different fractions: n‐hexane soluble fraction (HSF), dichloromethane soluble fraction (DMSF), ethyl acetate soluble fraction (EASF), and aqueous fraction (AQF). DMSF was chemically evaluated through chromatographic separation, and all the fractions including the crude methanolic extracts were assessed for their potential pharmacological activities against pain, oxidative stress, hyperglycemia, diarrhea, and microbes following standard protocols. Results: Chemical investigation results in the isolation of lupeol, β ‐sitosterol, and 1‐monostearin. The structures of the compounds were elucidated through meticulous NMR spectroscopic analysis. In a DPPH free radical scavenging assay, prominent action was noticed by EASF, with a median inhibition concentration (IC 50 ) of 24.207 g/mL in comparison to the BHT with an IC 50 value of 23.159 g/mL. In central analgesic activity, all the results were highly significant, with the highest (233.47%) time elongation in comparison to the control, observed after 90 min at 600 mg/kg b.w. and maximum peripheral analgesic activity of 61.96% was found at a dose of 600 mg/kg b.w. Two test doses (600 and 400 mg/kg b.w.) demonstrated substantial hypoglycemic and antidiarrheal effects that became more pronounced over time. The isolated compounds demonstrated impressive binding scores when interacting with glutathione reductase (3GRS), mu‐opioid receptor (MOR), kappa opioid receptor (KOR), and glucose transporter 3 (GLUT 3) receptors. However, their performance was notably lacking in terms of binding with cyclooxygenase‐2 (COX‐2) and dihydrofolate reductase (DHFR) receptors. Conclusion: Three isolated phytochemicals demonstrate promising binding affinities with the receptor molecules that support the pharmacological findings of this study. However, additional research needs to be conducted to isolate more phytoconstituents and affirm the pharmacological potential of J. gendarussa .
- 1 January 2025
- Published by Wiley in BioMed Research International
- Vol. 2025 (1)
Open AccessPhenolic Compounds of Justicia gendarussa Show Pharmacological Potentials Against Pain, Oxidation, Hyperglycemia, Diarrhea, and Microbes: Phytopharmacological and Computational Approaches
Background: Justicia gendarussa is a branched shrub spread across Indian, Sri Lankan, and Malaysian forests. It has been widely used across many countries to treat asthma, rheumatism, colics in children, eczema, and HIV. The study goal was to investigate the phytoconstituents from J. gendarussa and to discover its therapeutic potential against various disease conditions. Methods: The plant sample was collected, dried, and grinded into coarse powder which was then soaked in methanol for 2 weeks. After the maceration process, the crude methanolic extract was subjected to solvent–solvent partitioning into four different fractions: n‐hexane soluble fraction (HSF), dichloromethane soluble fraction (DMSF), ethyl acetate soluble fraction (EASF), and aqueous fraction (AQF). DMSF was chemically evaluated through chromatographic separation, and all the fractions including the crude methanolic extracts were assessed for their potential pharmacological activities against pain, oxidative stress, hyperglycemia, diarrhea, and microbes following standard protocols. Results: Chemical investigation results in the isolation of lupeol, β ‐sitosterol, and 1‐monostearin. The structures of the compounds were elucidated through meticulous NMR spectroscopic analysis. In a DPPH free radical scavenging assay, prominent action was noticed by EASF, with a median inhibition concentration (IC 50 ) of 24.207 g/mL in comparison to the BHT with an IC 50 value of 23.159 g/mL. In central analgesic activity, all the results were highly significant, with the highest (233.47%) time elongation in comparison to the control, observed after 90 min at 600 mg/kg b.w. and maximum peripheral analgesic activity of 61.96% was found at a dose of 600 mg/kg b.w. Two test doses (600 and 400 mg/kg b.w.) demonstrated substantial hypoglycemic and antidiarrheal effects that became more pronounced over time. The isolated compounds demonstrated impressive binding scores when interacting with glutathione reductase (3GRS), mu‐opioid receptor (MOR), kappa opioid receptor (KOR), and glucose transporter 3 (GLUT 3) receptors. However, their performance was notably lacking in terms of binding with cyclooxygenase‐2 (COX‐2) and dihydrofolate reductase (DHFR) receptors. Conclusion: Three isolated phytochemicals demonstrate promising binding affinities with the receptor molecules that support the pharmacological findings of this study. However, additional research needs to be conducted to isolate more phytoconstituents and affirm the pharmacological potential of J. gendarussa .
- Open Access
- 9 July 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 39, 101777
Relationship between oligoarginine-induced membrane damage of single Escherichia coli cells and entry of the peptide into the cytoplasm
- 9 July 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 39, 101777
Open AccessRelationship between oligoarginine-induced membrane damage of single Escherichia coli cells and entry of the peptide into the cytoplasm
- Open Access
- 1 January 2024
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2024 (1) , 4035987
Deciphering In Vitro and In Vivo Pharmacological Properties of Seed and Fruit Extracts of Flacourtia jangomas (Lour.) Raeusch
The objective of the study was to evaluate the pharmacological properties of the methanolic extract of Flacourtia jangomas (Lour.) Raeusch fruits (PFJM) and seeds (SFJM), along with their soluble fractions in ethyl acetate (fruit: PFJE; seed: SFJE) and chloroform (fruit: PFJC; seed: SFJC). Our phytochemical analysis of the examined extracts confirmed the presence of various therapeutically active phytoconstituents, including flavonoids, tannins, glycosides, and alkaloids. Employing the DPPH (2,2‐diphenyl‐1‐picrylhydrazyl) radical quenching method, SFJC exhibited the highest antioxidative potential, with an IC50 of 48.84, compared to ascorbic acid (IC50 21.77). The thrombolytic activity was assessed through rapid clot analysis of human blood samples, revealing that SFJC demonstrated the highest thrombolytic activity (60.99 ± 2.28%) compared to streptokinase (72.89 ± 2.19%). In the protein denaturation antiarthritic test, the PFJE and SFJC extracts exhibited significant potency, achieving results of 74.28 ± 1.16% and 79.25 ± 0.83%, respectively, at a dose of 500 μg/mL. All samples displayed notable anthelmintic activity by reducing Pheretima posthuma paralysis and death time in a dose‐dependent manner compared to albendazole. In both in vivo analgesic tests, SFJC demonstrated substantial (p < 0.01) pain inhibition percentages (tail immersion: 49.46%; acetic acid writhing: 66.43%) at a dose of 600 mg/kg. During neuropharmacological screening, all extracts significantly (p < 0.01; p < 0.05) and dose‐dependently decreased the mice’s locomotion activity and motor balance. In the thiopental‐induced sedation assay, SFJC significantly decreased the sleep latency time (4.18 ± 0.24 min) and increased the duration of sleep time (85.20 ± 2.39 min) at a higher dose. All samples notably reduced blood glucose levels in the oral glucose tolerance test in a dose‐responsive manner, and SFJC exhibited a considerable hypoglycemic impact (7.38 ± 0.44 mmoles/L at 600 mg/kg). The frequency of diarrheal episodes in mice during the antidiarrhea assessment was significantly decreased by the tested plant samples. These findings can serve as a reference for future endeavors to isolate pure bioactive compounds from this plant for the development of novel phytomedicines.
- 1 January 2024
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2024 (1) , 4035987
Open AccessDeciphering In Vitro and In Vivo Pharmacological Properties of Seed and Fruit Extracts of Flacourtia jangomas (Lour.) Raeusch
The objective of the study was to evaluate the pharmacological properties of the methanolic extract of Flacourtia jangomas (Lour.) Raeusch fruits (PFJM) and seeds (SFJM), along with their soluble fractions in ethyl acetate (fruit: PFJE; seed: SFJE) and chloroform (fruit: PFJC; seed: SFJC). Our phytochemical analysis of the examined extracts confirmed the presence of various therapeutically active phytoconstituents, including flavonoids, tannins, glycosides, and alkaloids. Employing the DPPH (2,2‐diphenyl‐1‐picrylhydrazyl) radical quenching method, SFJC exhibited the highest antioxidative potential, with an IC50 of 48.84, compared to ascorbic acid (IC50 21.77). The thrombolytic activity was assessed through rapid clot analysis of human blood samples, revealing that SFJC demonstrated the highest thrombolytic activity (60.99 ± 2.28%) compared to streptokinase (72.89 ± 2.19%). In the protein denaturation antiarthritic test, the PFJE and SFJC extracts exhibited significant potency, achieving results of 74.28 ± 1.16% and 79.25 ± 0.83%, respectively, at a dose of 500 μg/mL. All samples displayed notable anthelmintic activity by reducing Pheretima posthuma paralysis and death time in a dose‐dependent manner compared to albendazole. In both in vivo analgesic tests, SFJC demonstrated substantial (p < 0.01) pain inhibition percentages (tail immersion: 49.46%; acetic acid writhing: 66.43%) at a dose of 600 mg/kg. During neuropharmacological screening, all extracts significantly (p < 0.01; p < 0.05) and dose‐dependently decreased the mice’s locomotion activity and motor balance. In the thiopental‐induced sedation assay, SFJC significantly decreased the sleep latency time (4.18 ± 0.24 min) and increased the duration of sleep time (85.20 ± 2.39 min) at a higher dose. All samples notably reduced blood glucose levels in the oral glucose tolerance test in a dose‐responsive manner, and SFJC exhibited a considerable hypoglycemic impact (7.38 ± 0.44 mmoles/L at 600 mg/kg). The frequency of diarrheal episodes in mice during the antidiarrhea assessment was significantly decreased by the tested plant samples. These findings can serve as a reference for future endeavors to isolate pure bioactive compounds from this plant for the development of novel phytomedicines.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1857. Why do antibiotic become resistant in hospitalized patients? Evidence from tertiary healthcare facilities in Bangladesh
Antibiotic resistance among hospitalized patients is a growing concern due to irrational antibiotic consumption. Exploring the dynamics of antibiotic consumption including healthcare-seeking behavior is indispensable to minimizing the antibiotic resistance burden. This study explored the pattern of antibiotic consumption and healthcare-seeking behavior of patients before being admitted to tertiary hospitals in Bangladesh. Between August and September 2022, we conducted this cross-sectional study in four tertiary care ( 2 public and 2 private) hospitals. A total of 943 admitted patients were randomly enrolled and face-to-face interviews were conducted to obtain data on antibiotic usage history, healthcare-seeking patterns, and duration of medical consultation. Descriptive statistics were used for the analysis and interpretation. Prior to hospitalization, 32.8% (95%CI: 30.5, 35.1) of patients had antibiotic consumption history within the previous two months without lab confirmation. About one-quarter (25.6%) of the participants sought antibiotic treatment from unregistered physicians. Patients admitted to private hospitals were found to be higher to seek treatment from unregistered sources compared to public hospitals (37.8% vs. 13.4%, p-value: 0.001). Less than two-thirds (63.8%) of patients completed their entire course of antibiotics before admission to the hospitals. The average duration between symptom onset and medical consultation was 5.6 (SD 1.3) days before hospitalization. In terms of place for healthcare seeking, the majority of participants (52.0%) visited government hospitals, followed by private hospitals (22.6%), and pharmacies (20.1%). Self-medication was found in 5.3% of participants before being admitted to the hospital. However, 72.2% of patients were prescribed antibiotics after admission and only 5.3% had a laboratory diagnosis before receiving antibiotics. Hospitalized patients were found to consume antibiotics more frequently before and after admission. Furthermore, healthcare seeking from unregistered sources, including delayed and incomplete treatment could hindrance to combating against antibiotic resistance among admitted patients. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1857. Why do antibiotic become resistant in hospitalized patients? Evidence from tertiary healthcare facilities in Bangladesh
Antibiotic resistance among hospitalized patients is a growing concern due to irrational antibiotic consumption. Exploring the dynamics of antibiotic consumption including healthcare-seeking behavior is indispensable to minimizing the antibiotic resistance burden. This study explored the pattern of antibiotic consumption and healthcare-seeking behavior of patients before being admitted to tertiary hospitals in Bangladesh. Between August and September 2022, we conducted this cross-sectional study in four tertiary care ( 2 public and 2 private) hospitals. A total of 943 admitted patients were randomly enrolled and face-to-face interviews were conducted to obtain data on antibiotic usage history, healthcare-seeking patterns, and duration of medical consultation. Descriptive statistics were used for the analysis and interpretation. Prior to hospitalization, 32.8% (95%CI: 30.5, 35.1) of patients had antibiotic consumption history within the previous two months without lab confirmation. About one-quarter (25.6%) of the participants sought antibiotic treatment from unregistered physicians. Patients admitted to private hospitals were found to be higher to seek treatment from unregistered sources compared to public hospitals (37.8% vs. 13.4%, p-value: 0.001). Less than two-thirds (63.8%) of patients completed their entire course of antibiotics before admission to the hospitals. The average duration between symptom onset and medical consultation was 5.6 (SD 1.3) days before hospitalization. In terms of place for healthcare seeking, the majority of participants (52.0%) visited government hospitals, followed by private hospitals (22.6%), and pharmacies (20.1%). Self-medication was found in 5.3% of participants before being admitted to the hospital. However, 72.2% of patients were prescribed antibiotics after admission and only 5.3% had a laboratory diagnosis before receiving antibiotics. Hospitalized patients were found to consume antibiotics more frequently before and after admission. Furthermore, healthcare seeking from unregistered sources, including delayed and incomplete treatment could hindrance to combating against antibiotic resistance among admitted patients. All Authors: No reported disclosures
- Open Access
- 28 February 2022
- Published by SASPR Edu International Pvt. Ltd in SAS Journal of Medicine
- Vol. 8 (2) , 106-113
Metallo-Beta-Lactamase Producing Gram-Negative Bacteria among Patients in a Tertiary Care Hospital
- 28 February 2022
- Published by SASPR Edu International Pvt. Ltd in SAS Journal of Medicine
- Vol. 8 (2) , 106-113
Open AccessMetallo-Beta-Lactamase Producing Gram-Negative Bacteria among Patients in a Tertiary Care Hospital